Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.
PUBLICATIONS SHOULD BE DELIVERED SEPARATELY USING A SPREADSHEET PROGRAM (EXCEL OR SHEETS)
Dec 2020 | From Akero Therapeutics
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Jul 2018 | FROM EXTERNAL EXPERTS
A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling
Jun 2018 | FROM EXTERNAL EXPERTS
Recent advances in understanding and managing non-alcoholic fatty liver disease
